Levosimendan restores the positive force-frequency relation in heart failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 2, 2011, Pages

  Masutani, Satoshi ^a   Cheng, Heng Jie ^a   Tachibana, Hideo ^a   Little, William C ^a   Cheng, Che Ping ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Contractility; Diastole; Drugs; Heart rate

Indexed keywords

CALCIUM; LEVOSIMENDAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; EXPERIMENTAL DOG; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART PACING; HEART RATE; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; LOADING DRUG DOSE; MALE; NONHUMAN; POSITIVE FORCE FREQUENCY RELATION; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; TACHYCARDIA;

ANALYSIS OF VARIANCE; ANIMALS; CARDIAC PACING, ARTIFICIAL; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOGS; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART RATE; HYDRAZONES; MALE; MYOCARDIAL CONTRACTION; PYRIDAZINES; STROKE VOLUME; TACHYCARDIA; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 79961089188     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01116.2010     Document Type: Article

References (60)

1. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, Scheinin H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 23: 213-222, 2004.
2. 2+- sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 7: 882-887, 2005.
3. 2 consumption in dogs. Am J Physiol Heart Circ Physiol 294: H238-H248, 2008.
4. Bavendiek U, Brixius K, Munch G, Zobel C, Muller-Ehmsen J, Schwinger RH. Effect of inotropic interventions on the force-frequency relation in the human heart. Basic Res Cardiol 92, Suppl 1: 76-85, 1998.
5. Bristow MR. beta-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000.
6. 2+ sensitizer, levosimendan, in human myocardium. Am J Physiol Heart Circ Physiol 282: H131-H137, 2002.
7. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC. Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 78: 880-892, 1996.
8. Cheng CP, Ukai T, Onishi K, Ohte N, Suzuki M, Zhang ZS, Cheng HJ, Tachibana H, Igawa A, Little WC. The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure. Am J Physiol Heart Circ Physiol 280: H1853-H1860, 2001.
9. De Luca L, Colucci WS, Nieminen MS, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27: 1908-1920, 2006.
10. Dernellis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest 128: 2633-2639, 2005.
11. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113, 1995.
12. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 40: 323-338, 2002.
13. Endoh M. Force-frequency relationship in intact mammalian ventricular myocardium: physiological and pathophysiological relevance. Eur J Pharmacol 500: 73-86, 2004.
14. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, and Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO Study): a randomised double-blind trial. Lancet 360: 196-202, 2002.
15. Freeman GL, Little WC, O'Rourke RA. Influence of heart rate on the left ventricular performance in conscious dogs. Circ Res 61: 455-464, 1987.
16. Givertz MM, Andreou C, Conrad CH, Colucci WS. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation 115: 1218-1224, 2007.
17. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 26, Suppl 1: S10-S19, 1995.
18. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25: 794-801, 1995.
19. Harkin CP, Pagel PS, Tessmer JP, Warltier DC. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 26: 179-188, 1995.
20. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H. Influence of the novel inotropic agent, levosimendan, on isometric tension and calcium cycling in failing human myocardium. Circulation 98: 2141-2147, 1998.
21. Higashiyama A, Watkins MW, Chen Z, LeWinter MM. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 92: 3094-3104, 1995.
22. Higgins CB, Vatner SF, Eckberg DL, Braunwald E. Alterations in the baroreceptor reflex in conscious dogs with heart failure. J Clin Invest 51: 715-724, 1972.
23. Ho JE, Bittner V, DeMicco DA, Breazna A, Deedwania PC, Waters DD. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (data from the Treating New Targets [TNT] Trial). Am J Cardiol 105: 905-911, 2010.
24. Izawa H, Yokota M, Takeichi Y, Inagaki M, Nagata K, Iwase M, Sobue T. Adrenergic control of the force-frequency and relaxationfrequency relations in patients with hypertrophic cardiomyopathy. Circulation 96: 2959-2968, 1997.
25. Janssen PM, Datz N, Zeitz O, Hasenfuss G. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 404: 191-199, 2000.
26. Janssen PML, Stull LB, Marban E. Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. Am J Physiol Heart Circ Physiol 282: H499-H507, 2002.
27. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37: 367-374, 2001.
28. Kass DA. Force-frequency relation in patients with left ventricular hypertrophy and failure. Basic Res Cardiol 1, Suppl 93: 108-116, 1998.
29. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113: 305-315, 2006.
30. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 107: 81-86, 2003.
31. 2+ desensitization in failing rat myocardium. J Physiol 582: 695-709, 2007.
32. Lehtonen L, Poder P. The utility of levosimendan in the treatment of heart failure. Ann Med 39: 2-17, 2007.
33. Lenfant C. Report of the task force on research in heart failure. Circulation 90: 1118-1123, 1994.
34. Li L, Chu G, Kranias EG, Bers DM. Cardiac myocyte calcium transport in phospholamban knockout mouse: relaxation and endogenous CaMKII effects. Am J Physiol Heart Circ Physiol 274: H1335-H1347, 1998.
35. Little WC. The left ventricular dP/dtmax-end-diastolic volume relation in closed-chest dogs. Circ Res 56: 808-815, 1985.
36. Little WC, Cheng CP. Effect of exercise on left ventricular-arterial coupling assessed in the pressure-volume plane. Am J Physiol Heart Circ Physiol 264: H1629-H1633, 1993.
37. Masutani S, Cheng HJ, Hyttila-Hopponen M, Levijoki J, Heikkila A, Vuorela A, Little WC, Cheng CP. Orally available levosimendan: dose-related positive inotropic and lusitropic effect in conscious, chronically- instrumented normal and heart failure dogs. J Pharmacol Exp Ther 325: 236-247, 2008.
38. Masutani S, Little WC, Hasegawa H, Cheng HJ, Cheng CP. Restrictive left ventricular filling pattern does not result from increased left atrial pressure alone. Circulation 117: 1550-1554, 2008.
39. Miura T, Miyazaki S, Guth BD, Kambayashi M, Ross J,Jr. Influence of the force-frequency relation on left ventricular function during exercise in conscious dogs. Circulation 86: 563-571, 1992.
40. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI, Study Investigators RUSSLAN. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J 23: 1422-1432, 2002.
41. Morimoto A, Hasegawa H, Cheng HJ, Little WC, Cheng CP. Endogenous β3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 286: H2425-H2433, 2004.
42. Nozawa T, Cheng CP, Noda T, Little WC. Effect of exercise on left ventricular mechanical efficiency in conscious dogs. Circulation 90: 3047-3054, 1994.
43. Nozawa T, Yasumura Y, Futaki S, Tanaka N, Uenishi M, Suga H. Efficiency of energy transfer from pressure-volume area to external mechanical work increases with contractile state and decreases with afterload in the left ventricle of the anesthetized closed-chest dog. Circulation 77: 1116-1124, 1988.
44. Ohte N, Cheng CP, Little WC. Tachycardia exacerbates abnormal left ventricular-arterial coupling in heart failure. Heart Vessels 18: 136-141, 2003.
45. Ohte N, Cheng CP, Suzuki M, Little WC. Effects of atrial natriuretic peptide on left ventricular performance in conscious dogs before and after pacing-induced heart failure. J Pharmacol Exp Ther 291: 589-595, 1999.
46. Pagel PS, McGough MF, Hettrick DA, Lowe D, Tessmer JP, Jamali IN, Warltier DC. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol 29: 563-573, 1997.
47. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, Minami K, Just H, Hasenfuss G. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 92: 1169-1178, 1995.
48. Poder P, Eha J, Sundberg S, Antila S, Heinpalu M, Loogna I, Planken U, Rantanen S, Lehtonen L. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 41: 365-373, 2003.
49. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 30: 1115-1128, 1998.
50. Schwinger RH, Brixius K, Bavendiek U, Hoischen S, Muller-Ehmsen J, Bolck B, Erdmann E. Effect of cyclopiazonic acid on the forcefrequency relationship in human nonfailing myocardium. J Pharmacol Exp Ther 283: 286-292, 1997.
51. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol Heart Circ Physiol 245: H773-H780, 1983.
52. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, Cheng CP. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 288: H914-H922, 2005.
53. Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 279: 120-127, 1996.
54. Travill CM, Williams TD, Pate P, Song G, Chalmers J, Lightman SL, Sutton R, Noble MI. Haemodynamic and neurohumoral response in heart failure produced by rapid ventricular pacing. Cardiovasc Res 26: 783-790, 1992.
55. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68: 522-531, 2000.
56. Varian KD, Janssen PML. Frequency-dependent acceleration of relaxation involves decreased myofilament calcium sensitivity. Am J Physiol Heart Circ Physiol 292: H2212-H2219, 2007.
57. Wachter R, Schmidt-Schweda S, Westermann D, Post H, Edelmann F, Kasner M, Luers C, Steendijk P, Hasenfub G, Tschope C, Pieske B. Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure. Eur Heart J 30: 3027-3036, 2009.
58. 2+ store throughout cardiac myocyte. Circ Res 99: 283-291, 2006.
59. + channel in rat arterial myocytes. Eur J Pharmacol 333: 249-259, 1997.
60. + channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383, 1997.